Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
German company BioNTech warned on Tuesday that there is no data backing the”safety and efficacy” of delaying the next shot of its COVID-19 vaccine beyond three weeks, as some countries push the jab to provide more people their first dose.
BioNTech, which developed the vaccine with US giant Pfizer, said its clinical data showing 95 percent effectiveness was based on a two-dose schedule separated by 21 days.
“The efficacy and safety of this vaccine has not been evaluated on different dosing schedules,” it stated.
“Although data… demonstrated that there is a partial protection from the vaccine as early as 12 days after the first dose, there’s no data to demonstrate that protection after the initial dose is continuing after 21 days.”
Faced with limited supplies of these vaccines, Denmark said Monday it would space out the jabs up to six weeks, while Britain has said it would wait up to 12 weeks before giving the next jab.
Germany also is mulling pushing back the next shot to beyond 21 days.
Proponents state that practice would enable more of the people to receive their first jab.
“While decisions on other dosing regimens reside with health authorities, we believe a second dose is required to give the maximum protection against the disease,” BioNTech said.
Mainz-based BioNTech said it remains committed to continuing”dialogue with regulators, health authorities and governments” on”any public health decisions”.
